Magenta Therapeutics Announces Pricing of Initial Public Offering
CAMBRIDGE, Mass.–June 20, 2018 08:06 PM — Magenta Therapeutics, Inc., a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today announced the pricing of its initial public offering of 6,666,667 shares of its common stock at a price to the public of $15.00 per share, for total gross proceeds of approximately $100,000,000. In addition, the underwriters have a 30-day option to purchase up to 1,000,000 additional shares of common stock at the initial public offering price less underwriting discounts and commissions. The shares are expected to begin trading on the Nasdaq Global Market on June 21, 2018 under the symbol “MGTA.” The offering is expected to close on June 25, 2018, subject to customary closing conditions.
J.P. Morgan, Goldman Sachs & Co. LLC and Cowen are acting as joint book running managers for the offering. Wedbush PacGrow is acting as lead manager for the offering.
The proposed offering will be made only by means of a prospectus. When available, a copy of the preliminary prospectus may be obtained from:
- J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 866-803-9204
- Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing Prospectusemail@example.com
- Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, telephone: 631-274-2806.
A registration statement relating to the offering has been filed with, and declared effective by, the United States Securities and Exchange Commission (“SEC”). Copies of the registration statement can be accessed through the SEC’s website at www.sec.gov. This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful before registration or qualification under the securities laws of that state or jurisdiction.
About Magenta Therapeutics
Headquartered in Cambridge, Mass., Magenta Therapeutics is a clinical-stage biotechnology company developing therapeutics focused on critical areas of unmet need in the field of bone marrow transplant for patients with autoimmune diseases, blood cancers and genetic diseases.
This press release may contain forward-looking statements, including statements regarding Magenta’s financing plans and planned offering of common stock. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on management’s current beliefs, expectations and assumptions regarding the future of Magenta’s business, future plans and strategies, development plans, clinical results and other future conditions. Such statements are subject to certain risks and uncertainties, including, but are not limited to: uncertainties related to the initiation and conduct of trials and studies and other development requirements for Magenta’s product candidates; the risk that any one or more of Magenta’s product candidates will not be successfully developed and commercialized; the risk that the results of preclinical studies or clinical trials will be predictive of future results in connection with future studies or trials; risks related to Magenta’s ability to protect and maintain its intellectual property position; and risks related to Magenta’s relationships with third parties. Although Magenta’s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Magenta. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Magenta’s programs and operations are described in additional detail in its registration statement on Form S-1, which is on file with the SEC. Any forward-looking statement made in this press release speaks only as of the date on which it is made. Magenta undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.